Prospective evaluation of ambulatory laser vaporization of the prostate for benign prostatic hyperplasia
Autor: | F. Trifard, R. Huet, Karim Bensalah, Sébastien Vincendeau, Fabien Bouliere, Emmanuel Della Negra, Gregory Verhoest, Romain Mathieu, Y. Codet, G. Berquet, L. Corbel |
---|---|
Rok vydání: | 2015 |
Předmět: |
medicine.medical_specialty
business.industry medicine.medical_treatment 030232 urology & nephrology Urology Dermatology Perioperative Hyperplasia medicine.disease 3. Good health Surgery 03 medical and health sciences 0302 clinical medicine medicine.anatomical_structure Ambulatory care Quality of life Prostate 030220 oncology & carcinogenesis Ambulatory Medicine International Prostate Symptom Score business Transurethral resection of the prostate |
Zdroj: | Lasers in Surgery and Medicine. 47:396-402 |
ISSN: | 0196-8092 |
DOI: | 10.1002/lsm.22363 |
Popis: | Background and objective Photoselective vaporization of the prostate (PVP) is an alternative to transurethral resection of the prostate in the surgical treatment of benign prostatic hyperplasia (BPH). Our objective was to prospectively evaluate the feasibility, safety, and efficacy of ambulatory photoselective vaporization of the prostate for benign prostatic hyperplasia. Materials and Methods We prospectively collected data of all consecutive patients who underwent ambulatory PVP with the Greenlight® laser 180-W XPS at two centers between May 2012 and June 2013. Patients' characteristics, perioperative data, postoperative outcomes, complications, and patient's satisfaction were evaluated. Successful ambulatory care procedure was defined as the ability to leave the hospital in the evening of the operation. Results The ambulatory procedure was intended in 134 patients. Mean age was 67 years. Mean prostate volume was 54 ml, and Median American Society Anesthesiologists (ASA) score was 2. Ambulatory procedure was successful in 121 patients (90%). At 3 months, International Prostate Symptom Score (7.3 ± 4.9), maximal urinary flow rate (20.8 ± 7.6 ml/s), postvoid residual urine (19.2 ± 71 ml), and quality of life (1.6 ± 1.4) were significantly improved (P |
Databáze: | OpenAIRE |
Externí odkaz: |